Evidence map›Paper›PMID 35302997›Full record

ArticlePloS one2022

Analysis of accumulated SARS-CoV-2 seroconversion in North Carolina: The COVID-19 Community Research Partnership.

John C Williamson, Thomas F Wierzba, Michele Santacatterina, Iqra Munawar, Austin L Seals, Christine Ann Pittman Ballard, Martha Alexander-Miller, Michael S Runyon, Lewis H McCurdy, Michael A Gibbs and 13 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 1 country.

John C WilliamsonDepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.ORCID 0000-0002-3840-7143
Thomas F WierzbaDepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.
Michele SantacatterinaDepartment of Biostatistics and Bioinformatics, Biostatistics Center, George Washington University, Rockville, Maryland, United States of America.
Iqra MunawarDepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.
Austin L SealsDepartment of Internal Medicine, Section on Cardiovascular Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.
Christine Ann Pittman BallardDepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.
Martha Alexander-MillerDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.
Michael S RunyonDepartment of Emergency Medicine, Atrium Health's Carolinas Medical Center, Charlotte, North Carolina, United States of America.
Lewis H McCurdyDepartment of Internal Medicine, Division of Infectious Diseases, Atrium Health, Charlotte, North Carolina, United States of America.
Michael A GibbsDepartment of Emergency Medicine, Atrium Health's Carolinas Medical Center, Charlotte, North Carolina, United States of America.
Amina AhmedDepartment of Pediatrics, Atrium Health, Charlotte, North Carolina, United States of America.
William H LagardeDepartment of Pediatrics, WakeMed Health and Hospitals, Raleigh, North Carolina, United States of America.
Patrick D MaguireDepartment of Radiation Oncology, New Hanover Regional Medical Center, Wilmington, North Carolina, United States of America.
Robin King-ThieleCampbell University School of Osteopathic Medicine, Lillington, North Carolina, United States of America.
Terri HamrickCampbell University School of Osteopathic Medicine, Lillington, North Carolina, United States of America.
Abdalla IhmeidanCampbell University School of Osteopathic Medicine, Lillington, North Carolina, United States of America.
Shakira HendersonCenter for Research and Grants, Vidant Health, Greenville, North Carolina, United States of America.
T Ryan GallaherDepartment of Infectious Diseases, Vidant Health, Greenville, North Carolina, United States of America.
Diane UschnerDepartment of Biostatistics and Bioinformatics, Biostatistics Center, George Washington University, Rockville, Maryland, United States of America.ORCID 0000-0002-7858-796X
Sharon L EdelsteinDepartment of Biostatistics and Bioinformatics, Biostatistics Center, George Washington University, Rockville, Maryland, United States of America.
David M HerringtonDepartment of Internal Medicine, Section on Cardiovascular Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.
John W SandersDepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America.
North Carolina sites of the COVID-19 Community Research Partnership
Atrium Health Wake Forest Baptist · USCampbell University · USGeorge Washington University · USAtrium Medical Cente · USCarolinas Medical Center · USVidant Health · USNew Hanover Regional Medical Center · USWake Forest University · USWakeMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 Community Research Partnership is a population-based longitudinal syndromic and sero-surveillance study. The study includes over 17,000 participants from six healthcare systems in North Carolina who submitted over 49,000 serology results. The purpose of this study is to use these serology data to estimate the cumulative proportion of the North Carolina population that has either been infected with SARS-CoV-2 or developed a measurable humoral response to vaccination.

methodsAdult community residents were invited to participate in the study between April 2020 and February 2021. Demographic information was collected and daily symptom screen was completed using a secure, HIPAA-compliant, online portal. A portion of participants were mailed kits containing a lateral flow assay to be used in-home to test for presence of anti-SARS-CoV-2 IgM or IgG antibodies. The cumulative proportion of participants who tested positive at least once during the study was estimated. A standard Cox proportional hazards model was constructed to illustrate the probability of seroconversion over time up to December 20, 2020 (before vaccines available). A separate analysis was performed to describe the influence of vaccines through February 15, 2021.

results17,688 participants contributed at least one serology result. 68.7% of the population were female, and 72.2% were between 18 and 59 years of age. The average number of serology results submitted per participant was 3.0 (±1.9). By December 20, 2020, the overall probability of seropositivity in the CCRP population was 32.6%. By February 15, 2021 the probability among healthcare workers and non-healthcare workers was 83% and 49%, respectively. An inflection upward in the probability of seropositivity was demonstrated around the end of December, suggesting an influence of vaccinations, especially for healthcare workers. Among healthcare workers, those in the oldest age category (60+ years) were 38% less likely to have seroconverted by February 15, 2021.

conclusionsResults of this study suggest more North Carolina residents may have been infected with SARS-CoV-2 than the number of documented cases as determined by positive RNA or antigen tests. The influence of vaccinations on seropositivity among North Carolina residents is also demonstrated. Additional research is needed to fully characterize the impact of seropositivity on immunity and the ultimate course of the pandemic.

Indexed as

AdultAge FactorsAntibodies, ViralCommunity ParticipationCOVID-19FemaleHealth PersonnelHumansLongitudinal StudiesMaleMiddle AgedNorth CarolinaSARS-CoV-2SeroconversionYoung AdultAntibodies, Viral

Identifiers

PMID35302997
PMCPMC8932589
OpenAlexW4220905910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.